MilliporeSigma and Schneider Electric announced the signing of a Memorandum of Understanding (MoU) that aims to automate biopharmaceutical processes for China’s biopharmaceutical industry. The MoU outlines the companies plan to form a co-marketing relationship for the automation.
“We are living in a fast-paced, evolving life science environment in which more chronic diseases are prevalent,” said Andrew Bulpin, head of the Process Solutions business area, Life Science, at MilliporeSigma. “The global and local players are investing heavily in pharmaceutical research and biosimilars, racing against time to find therapeutic solutions and treat patients faster and more effectively. Schneider Electric’s automation solutions combined with our hardware, software and single-use consumables would enable an automated biopharmaceutical solution for our respective customers. We look forward to helping our biopharma customers in their quest for reliable, less expensive and better medical solutions.”
The Process Solutions area within MilliporeSigma’s Life Science business provides a portfolio of products and services for biopharmaceutical manufacturing. Combining the technical expertise of MilliporeSigma and the technological capabilities of Schneider Electric, the collaboration would give customers greater flexibility and save them time.